Hoffmann K, Cazemier K, Baldow C, Schuster S, Kheifetz Y, Schirm S, Horn M, Ernst T, Volgmann C, Thiede C, Hochhaus A, Bornhäuser M, Suttorp M, Scholz M, Glauche I, Loeffler M, Roeder I
Integration of mathematical model predictions into routine workflows to support clinical decision making in haematology.
BMC medical informatics and decision making 20(1) 2020, 28, DOI Link
Hähnel T, Baldow C, Guilhot J, Guilhot F, Saussele S, Mustjoki S, Jilg S, Jost PJ, Dulucq S, Mahon FX, Roeder I, Fassoni AC, Glauche I
Model-based inference and classification of immunological control mechanisms from TKI cessation and dose reduction in CML patients.
Cancer research 80(11) 2020, 2394-2406, DOI Link
Glauche I, Kuhn M, Baldow C, Schulze P, Rothe T, Liebscher H, Roy A, Wang X, Roeder I
Quantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparison.
Scientific Reports 8, 2018, 12330, DOI Link
Fassoni AC, Baldow C, Roeder I, Glauche I
Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: A simulation study based on phase 3 trial data
Haematologica 103(11) 2018, 1825-1834, DOI Link
Proschmann R, Baldow C, Rothe T, Suttorp M, Thiede C, Tauer JT, Müller MC, Hochhaus A, Roeder I, Glauche I
Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
Haematologica 102(2) 2017, e39-e42, DOI Link
Baldow C, Salentin S, Schroeder M, Roeder I, Glauche I
MAGPIE: Simplifying access and execution of computational models in the life sciences
PLOS Computational Biology 13(12) 2017, 1-11, DOI Link
Baldow C, Thielecke L, Glauche I
Model Based Analysis of Clonal Developments Allows for Early Detection of Monoclonal Conversion and Leukemia
PLoS ONE 11(10) 2016, e0165129, DOI Link
Isik Z, Baldow C, Cannistraci CV, Schroeder M
Drug target prioritization by perturbed gene expression and network information.
Scientific reports 5, 2015, 17417, DOI Link
Glauche I, Baldow Ch, Fröhlich S, Schulze P, Roy A, Subar M, Wang X, Roeder I
Model-Based Characterization of the Molecular Response Dynamics of Tyrosine Kinase Inhibitor (TKI)-Treated CML Patients a Comparison of Imatinib and Dasatinib First-Line Therapy
Blood 124, 2014, 4562